For US residents only.

How Treatment May Help

Sandostatin® LAR Depot (octreotide acetate for injectable suspension)

When you get a diagnosis of severe diarrhea and flushing associated with carcinoid syndrome, your first thought may be, “What now?” There’s a treatment option like Sandostatin® LAR Depot (octreotide acetate for injectable suspension). Sandostatin® (octreotide acetate) Immediate-release Injection is a medicine approved in 1988 to treat the severe diarrhea and flushing associated with carcinoid syndrome. It may help you control your symptoms and live in the moment.

Treating patients for over 28 years*

*Includes Sandostatin® (octreotide acetate) Immediate-release Injection and Sandostatin® LAR Depot (octreotide acetate for injectable suspension) for all approved indications.

Symptom Control You Can Count On

Here are results from a clinical study of 92 patients with carcinoid syndrome who were treated with Sandostatin LAR Depot or Sandostatin Immediate-release Injection.§

A 6-month clinical trial of malignant carcinoid syndrome was performed in patients who had previously been shown to be responsive to Sandostatin® (octreotide acetate) Immediate-release Injection.

Patients received 10-mg, 20-mg, or 30-mg doses of Sandostatin LAR Depot every 28 days or continued their Sandostatin Immediate-release Injection regimen.

§Patients receiving Sandostatin LAR Depot who experienced symptom flare-ups were permitted to use supplemental Sandostatin Immediate-release Injection until symptoms were again controlled to screening frequency.

Sandostatin® (octreotide acetate) is the only somatostatin analogue approved to treat severe diarrhea and flushing associated with carcinoid syndrome.